New combo therapy aims to wipe out breast cancer before surgery

This study tests whether adding an immune-boosting drug called eftilagimod alpha to standard chemotherapy before surgery can completely eliminate tumors in people with early-stage hormone receptor-positive, HER2-negative breast cancer. About 50 participants will receive the drug combination, and researchers will check the removed tissue for any remaining cancer cells. The goal is to improve the chance of a complete response, which may reduce the risk of the cancer coming back.